


## Type 1 Diabetes is Increasing its Prevalence



Existing diabetes management strategies are extremely complex and burdensome, leading to suboptimal patient outcomes

1.6M

in the US are living with type I diabetes


187K

under the age of 20 have type I diabetes



600K

type I diabetes in kids under the age of 20 by 2050

## Current Solutions Introduce Variability



Nearly all diabetes technologies employ subcutaneous delivery, an inconsistent method that delays insulin delivery to the body and makes it unpredictable.



## Living With Diabetes is Burdensome and Scary

One in four people with type 1 diabetes has high levels of diabetes distress...




"I have examples among my female patients who succeeded in giving birth to several babies thanks to the glucose control they reached with an implantable insulin pump. Without it, any pregnancy would have been an unachievable dream." - Physician Interviews

"My constant worry is the risk of developing diabetic complications - this is always on my mind and being around for my husband and family. I worry that if I have a bad day I am increasing my risk of developing serious complications." - Aruna



"I always feel lucky, I feel more energized with [an IP] pump, and going off of the therapy is sort of a dreaded feeling for me because I really don't want to go back to traditional therapies and have all of that energy taken away from me" - Anne (Medtronic Minimed)


## The Solution



'Plug and play' with most commercial insulin pumps

## IP Provides Superior Kinetics and Physiological Delivery

	Subcutaneous	Intraperitoneal
Insulin Absorption (1st detection)	5-30 min.	1 min.
Insulin Absorption Peak	50-60 min.	15 min.
Duration of Insulin Action	4-6 hours	1-2 hours
Reproducibility of Absorption	20-30% variability (multiple skin delivery sites)	Consistent delivery site (single delivery site)
Insulin Delivery Route	Non-physiological delivery peripheral circulation	Physiological delivery to liver - just as a healthy pancreas




A tightly controlled range is associated with reduced adverse events and fewer future complications.

## Previous IP Systems Have Had Limitations

	Perikinetix: IDC (US & EU)	Roche: Accu-Check Diaport (EU only)	Medtronic: MiniMed (EU only)
Discreet Implant + Catheter	✓	X	X
External Pump	✓	✓	X
Low Infection Risk	✓	X	✓
Dehumanizing Ostomy in Abdomen	✓	X	✓
Occlusion-free	✓	✓	X

## Large Market Opportunity



## Economic Benefits

### Patients

- Cheaper insulin
- Fewer infusion sets
- Compatible with existing pumps

### Physicians

- Endocrinologist
- Primary Care
- Laparoscopic Surgeons

### Payers

- Reduced long-term costs
- 3.5x fewer hospital stays
- 2x fewer severe hypoglycemic events

## What We Are Doing

